Reflector

Looking back at the agenda of a 1985 EFPIA conference, Reflector sees that, three decades on, the European drug industry is still seeking a pill for its own ills.

Scope of supplementary protection certificate (SPC) could change.

In the coming weeks, the EU will decide if the degree of protection offered to drug firms by research incentives such as the SPC are really in the interests of patients and society. Reflector reports.

Reflector reports on the EU's legislative move to push the fifty or so national and regional HTA organizations in Europe towards greater cooperation.

For the pharma sector across Europe, Brexit is just one of the tough issues to think about, writes Reflector.

Is getting more clarity on Brexit ramifications for pharma and European public health really at the top of new-year to-do lists?

New action plan urges tighter alignment of public health policy with the development of targeted therapies.

Can health stakeholders be friends without being captives?

European Commission talks drug industry investment, health issues during State of the Union.

Reflector asks if the UK's newly announced post-Brexit life sciences strategy report is worth a look as a springboard to addressing future EU ties in healthcare, or just more bluster?

Is report worth a look as potential springboard to addressing future EU ties in healthcare-or just more bluster?

A review of the top contenders to land the agency as decision on its relocation draws closer.

Last week’s EFPIA and EU Health Council annual conferences highlighted the growing divisions-and resentments-between industry and governments on drug pricing. Reflector reports.

Several interventions and developments across the continent likely to keep discussions around drug affordability on high burn.

The recent EFPIA and EU health council conferences highlight the growing divisions-and resentments-between industry and governments in Europe.

In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector.

Grant-boosted Euripid pushes revitalized defense of external reference pricing system.

The external reference pricing circus has rolled back into town, promising another great European show. The fight-back comes via one of Europe's most obscure bodies, the European Integrated Price Information Database-better known as Euripid.

It is hard to resist the sensation that the rhetoric of Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.

It is hard to resist the sensation that the rhetoric of that Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.

The European Commission's latest economic assessment of EU member states does not make for comfortable reading, writes Reflector.

The long-cherished dream of finding a European approach to assessing the value of new medicines seems to recede further with every step taken to pursue it, writes Reflector.

The pursuit of a harmonized European approach to assessing the value of new medicines continues to face roadblocks.

2016 has been the year of the unpredictable - and the uncertainties this has generated will multiply and dominate the agenda in Europe in 2017, writes Reflector.

The European Medicine Association is determined keep open all options on the future of drug approvals in advance of a crucial meeting in December, writes Peter O'Donnell.

Cancer treatment is an increasing dilemma for EU health services as they try to balance patient care against budgetary constraints.

Cancer treatment is an increasing dilemma for health services as they try to balance patient care against budgetary constraints.

The potential collapse of the CETA agreement jeopardizes EU’s overall trade footing.

Can pharma help to salvage the EU's Comprehensive Economic and Trade Agreement with Canada in the face of resistance? Reflector reports.

Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.